原发性胆汁性肝硬化的药物治疗研究进展

王倩; 姚定康

doi:10.3969/j.issn.1001-5256.2014.05.022

原发性胆汁性肝硬化的药物治疗研究进展

DOI: 10.3969/j.issn.1001-5256.2014.05.022

王倩,
姚定康

第二军医大学第二附属医院

详细信息

中图分类号: R575.22
计量
- 文章访问数: 3063
- HTML全文浏览量: 14
- PDF下载量: 871
- 被引次数: 0
出版历程
- 出版日期: 2014-05-20

Research progress in medical treatment of primary biliary cirrhosis

摘要

摘要:
原发性胆汁性肝硬化(PBC)是一种自身免疫性疾病,熊去氧胆酸(UDCA)是唯一经随机对照临床试验证实治疗PBC安全有效的一线治疗药物,对于UDCA反应不佳者亟需其他有效的药物治疗。回顾了UDCA的疗效,重点叙述了对UDCA反应不佳者的备选治疗和辅助治疗的分类和最新研究进展,评估了药物的疗效和治疗前景,但布地奈德、依那西普等免疫抑制剂和其他类药物的疗效有待更多长期临床试验来验证。一些新兴的PBC分子疗法正处于积极的临床研究中。目前,对UDCA反应欠佳者的药物治疗方法尚不确定,尽管研究表明部分药物可以改善肝功能和肝脏生化指标,尚无确切的证据证明可改善长期预后。
- 肝硬化,胆汁性 /
- 自身免疫疾病 /
- 综述
Abstract:
Primary biliary cirrhosis ( PBC) is an autoimmune disease. Ursodeoxycholic acid ( UDCA) is the only safe and effective drug for the treatment of PBC, as proved by randomized controlled clinical trials, so it is advocated as first- line therapy. Alternative therapies are urgently needed for patients with poor response to UDCA. In addition to the efficacy of UDCA, the classification of alternative and adjuvant therapies for UDCA nonresponders and the latest research progress in these therapies are reviewed; the efficacy of existing drugs and treatment prospects are evaluated, but more long- term clinical studies are needed to confirm the efficacy of immunosuppressants such as budesonide and etanercept and other drugs. A number of novel molecular therapies for PBC are also undergoing clinical trials. There is currently no consensus on the medical treatment for patients with poor response to UDCA. Although studies have shown that some drugs can improve liver function and liver biochemistries, there is no definitive evidence that they improve long- term outcome.
- liver cirrhosis, biliary /
- autoimmune diseases /
- review

HTML全文

参考文献(33)

[1]LIU JT.The role and significance of autoantibodies in the clinical diagnosis of autoimmune liver disease[J].Chin J Immunol, 2013, 29 (6) :669-672. (in Chinese) 刘金涛.自身抗体在临床自身免疫性肝病中的作用和诊断意义[J].中国免疫学杂志, 2013, 29 (6) :669-672.

[2] KIM KA, JEONG SH.The diagnosis and treatment of primary biliary cirrhosis[J].Korean J Hepatol, 2011, 17 (3) :173-179.

[3]DU HH, LI QM, ZHOU XZ, et al.Diagnostic value of a variety of auto antibodies detection in patients with primary biliary cirrhosis[J].Chin J liver Dis:Electron Vers, 2013, 5 (1) :19-23. (in Chinese) 杜慧慧, 李青敏, 周希禛, 等.多种自身抗体联合检测在原发性胆汁性肝硬化中的诊断价值[J].中国肝脏病杂志:电子版, 2013, 5 (1) :19-23.

[4]SHI J, WU C, LIN Y, et al.Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis:a meta-analysis of randomized controlled trials[J].Am J Gastroenterol, 2006, 101 (7) :1529-1538.

[5]ZHU J, SHI Y, ZHOU X, et al.Observation on therapeutic efficacy of ursodeoxycholic acid in Chinese patients with primary biliary cirrhosis:a 2-year follow-up study[J].Front Med, 2013, 7 (2) :255-263.

[6]DUAN WJ, YOU H.Therapy advances in primary biliary cirrhosis[J].J Clin Hepatol, 2011, 27 (6) :719-720. (in Chinese) 段维佳, 尤红.原发性胆汁性肝硬化的治疗进展[J].临床肝胆病杂志, 2011, 27 (6) :581.

[7]RAUTIAINEN H, KARKKAINEN P, KARVONEN AL, et al.Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis:a three-year randomized trial[J].Hepatology, 2005, 41 (4) :747-752.

[8]TRIVEDI PJ, HIRSCHFIELD GM.Treatment of autoimmune liver disease:current and future therapeutic options[J].Ther Adv Chronic Dis, 2013, 4 (3) :119-141.

[9]JOIN E.EASL Clinical Practice Guidelines:management of cholestatic liver diseases[J].J Hepatol, 2009, 51 (2) :237-267.

[10]KIM KA, JEONG SH.The diagnosis and treatment of primary biliary cirrhosis[J].Korean J Hepatol, 2011, 17 (3) :173-179.

[11]KUBO S, IWATA S, SAITO K, et al.Successful treatment of primary biliary cirrhosis with etanercept in a patient with rheumatoid arthritis[J].Joint Bone Spine, 2011, 78 (5) :535-536.

[12]CAMPANATI A, GANZETTI G, DI SARIO A, et al.The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis[J].J Gastroenterol, 2013, 48 (7) :839-846.

[13]EFE C.Drug induced autoimmune hepatitis and TNF-αblocking agents:Is there a real relationship?[J].Autoimmun Rev, 2013, 12 (3) :337-339.

[14]STOJAKOVIC T, CLAUDEL T, PUTZ-BANKUTI C, et al.Lowdose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment[J].Atherosclerosis, 2010, 209 (1) :178-183.

[15]LEVY C, PETER JA, NELSON DR, et al.Pilot study:fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid[J].Aliment Pharmacol Ther, 2011, 33 (2) :235-242.

[16]KANDA T, YOKOSUKA O, IMAZEKI F, et al.Bezafibrate treatment:a new medical approach for PBC patients?[J].J Gastroenterol, 2003, 38 (6) :573-578.

[17]IWASAKI S, OHIRA H, NISHIGUCHI S, et al.The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis:A prospective, multicenter study[J].Hepatol Res, 2008, 38 (6) :557-564.

[18]PINES A, FISMAN EZ.ACE Inhibition with moexipril:a review of potential effects beyond blood pressure control[J].Am J Cardiovasc Drugs, 2003, 3 (5) :351-360.

[19]CHARATCHAROENWITTHAYA P, TALWALKAR JA, ANGULO P, et al.Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid[J].Digest Dis Sci, 2010, 55 (2) :476-483.

[20]COMBES B, EMERSON S, FLYE N, et al.Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis[J].Hepatology, 2005, 42 (5) :1184-1193.

[21]GONG Y, CHRISTENSEN E, GLUUD C.Azathioprine for primary biliary cirrhosis[J].Cochrane Database Syst Rev, 2007, 18 (3) :CD006000.

[22]GONG Y, CHRISTENSEN E, GLUUD C.Cyclosporin A for primary biliary cirrhosis[J].Cochrane Database Syst Rev, 2007, 18 (3) :CD005526.

[23]ASKARI F, INNIS D, DICK RB, et al.Treatment of primary biliary cirrhosis with tetrathiomolybdate:results of a double-blind trial[J].Transl Res, 2010, 155 (3) :123-130.

[24]HOU G, ABRAMS G, DICK R, et al.Efficacy of tetrathiomolybdate in a mouse model of multiple sclerosis[J].Transl Res, 2008, 152 (5) :239-244.

[25]CORPECHOT C.Primary biliary cirrhosis and bile acids[J].Clin Res Hepatol Gastroenterol, 2012, 36 (1) :s13-s20.

[26]KOWDLEY K, JONES D, LUKETIC V, et al.An international study evaluating the farnesoid X receptor agonist obeticholic acid as monotherapy in PBC[J].J Hepatol, 2011, 54:s13.

[27]ZHANG W, FEI Y, GAO J, et al.The role of CXCR3 in the induction of primary biliary cirrhosis[J].Clin Dev Immunol, 2011, 2011:564062.

[28]HINTERMANN E, BAYER M, PFEILSCHIFTER J, et al.CXCL10 promotes liver fibrosis by prevention of NK cell mediated hepatic stellate cell inactivation[J].J Autoimmun, 2010, 35 (4) :424-435.

[29]LLEO A, GERSHWIN M, MANTOVANI A, et al.Towards common denominators in primary biliary cirrhosis:the role of IL-12[J].J Hepatol, 2012, 56 (3) :731-733.

[30] HIRSCHFIELD G, LIU X, XU C, et al.Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants[J].N Engl J Med, 2009, 360 (24) :2544-2555.

[31]MELLS G, FLOYD J, MORLEY K, et al.Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis[J].Nat Genet, 2011, 43 (4) :329-332.

[32] MYERS RP, SWAIN MG, LEE SS, et al.B-Cell Depletion With Rituximab in Patients With Primary Biliary Cirrhosis Refractory to Ursodeoxycholic Acid[J].Am J Gastroenterol, 2013, 108 (6) :933-941.

[33]TSUDA M, MORITOKI Y, LIAN ZX, et al.Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid[J].Hepatology, 2012, 55 (2) :512-521.

施引文献

资源附件(0)

访问统计